TVRD
NASDAQ · Pharmaceuticals
Tvardi Therapeutics Inc
$1.87
+0.02 (+1.08%)
Financial Highlights (FY 2026)
Revenue
42.64M
Net Income
-423,395,713
Gross Margin
91.3%
Profit Margin
-993.0%
Rev Growth
-32.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.3% | 91.3% | 39.9% | 39.9% |
| Operating Margin | -919.4% | -827.5% | 28.0% | 29.2% |
| Profit Margin | -993.0% | -943.3% | 27.6% | 20.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 42.64M | 62.98M | 10.81M | 8.76M |
| Gross Profit | 38.93M | 57.51M | 4.32M | 3.50M |
| Operating Income | -392,044,722 | -521,182,052 | 3.03M | 2.56M |
| Net Income | -423,395,713 | -562,859,884 | 2.98M | 1.76M |
| Gross Margin | 91.3% | 91.3% | 39.9% | 39.9% |
| Operating Margin | -919.4% | -827.5% | 28.0% | 29.2% |
| Profit Margin | -993.0% | -943.3% | 27.6% | 20.0% |
| Rev Growth | -32.3% | -32.3% | +19.2% | +16.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 10.02M | 11.15M |
| Total Equity | — | — | 11.02M | 11.87M |
| D/E Ratio | — | — | 0.91 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -390,900,973 | -548,531,646 | 3.89M | 3.58M |
| Free Cash Flow | — | — | 2.37M | 1.91M |